This inventor holds 1 USPTO granted patent. Top assignee: University of California. Active years: 2014.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2014
Title: Innovations by Sunganya Viriyakosol
Introduction
Sunganya Viriyakosol is an accomplished inventor based in San Diego, CA. He has made significant contributions to the field of medical science, particularly in the development of targeted therapies for infectious diseases. His work focuses on innovative methods to combat sepsis, a life-threatening condition caused by infections.
Latest Patents
Sunganya holds a patent for "Compositions and methods using MD-2 mutants and chimeric proteins." This invention provides compositions and methods for targeted bacteriostatic and antibacterial agents, specifically aimed at treating sepsis caused by infectious diseases, including bacterial and fungal infections. The patent outlines methods for decreasing the levels of LPS in the circulation of individuals, such as human patients suffering from gram-negative septic shock. It also details the creation of chimeric proteins that incorporate the MD-2 polypeptide along with opsonizing agents, such as antibody Fc domains. Furthermore, the invention includes pharmaceutical compositions comprising these chimeric polypeptides and methods for their use in ameliorating or preventing sepsis.
Career Highlights
Sunganya Viriyakosol is affiliated with the University of California, where he continues to advance his research and innovations. His work has garnered attention for its potential impact on treating severe infections and improving patient outcomes.
Collaborations
Sunganya collaborates with Theo N Kirkland, III, enhancing the scope and depth of his research endeavors. Their partnership exemplifies the collaborative spirit often found in academic and research institutions.
Conclusion
Sunganya Viriyakosol's innovative work in the field of medical science, particularly through his patent on MD-2 mutants and chimeric proteins, showcases his commitment to addressing critical health challenges. His contributions have the potential to significantly improve treatment options for patients suffering from sepsis.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile